[Form 4] Cardiff Oncology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

On 20 June 2025, SNDL Inc. submitted a routine Form 6-K to the U.S. Securities and Exchange Commission.

The filing is primarily administrative and incorporates three exhibits into multiple Form S-8 registration statements:

• Exhibit 99.1: Notice of Meeting and Information Circular (dated 20 June 2025)
• Exhibit 99.2: Form of Proxy
• Exhibit 99.3: Notice-and-Access Notice

The report was signed by General Counsel & Corporate Secretary Matthew Husson. No financial statements, earnings results, or strategic transactions accompany the submission, indicating that the document is a standard compliance update rather than a material event. Consequently, the filing is unlikely to influence near-term valuation or market perception.

Insights

Financial Analyst

TL;DR: Routine administrative 6-K; negligible market impact

SNDL’s Form 6-K simply attaches proxy and meeting materials to existing S-8 registrations. No new financial data, guidance, or strategic shifts are provided, so investors should view the filing as compliance housekeeping with no direct earnings implications.

Corporate Governance Expert

TL;DR: Filing fulfills disclosure obligations; governance standard

By releasing its 2025 meeting notice and proxy via Form 6-K, SNDL demonstrates adherence to SEC rules for foreign issuers and ensures U.S. shareholders have timely access to governance documents. The action is procedural and raises no governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TANNENBAUM RENEE P

(Last) (First) (Middle)

C/O CARDIFF ONCOLOGY, INC.

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$3.16	06/26/2025		A		40,565		06/26/2026	06/26/2035	Common Stock	40,565	$0	168,766	D

Explanation of Responses:

	/s/ Renee Tannenbaum	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SNDL (SNDL) file with the SEC on 20 June 2025?

A Form 6-K that attaches notice of meeting, proxy, and notice-and-access materials.

Which exhibits are included in SNDL’s June 2025 Form 6-K?

Exhibit 99.1: Meeting notice & circular; Exhibit 99.2: Form of Proxy; Exhibit 99.3: Notice-and-Access Notice.

Does the filing contain any financial results or earnings guidance?

No. The 6-K presents no financial statements, earnings data, or guidance.

Why are the exhibits being incorporated by reference into Form S-8 registrations?

Inclusion ensures employee equity plans covered by the S-8s reference the current meeting and proxy documents for regulatory completeness.